top of page
The Professional Network for Healthcare Experts
Boehringer Ingelheim signs Sino Biopharmaceutical oncology deal worth up to $7.36 billion
Boehringer Ingelheim has entered a major oncology partnership with Sino Biopharmaceutical covering six preclinical antibody-drug conjugate and T-cell engager programmes, with potential payments reaching approximately $7.36 billion.
nuaxia
6 days ago2 min read
Roche signs Hansoh Pharma oncology ADC collaboration with more than $15 billion in potential milestones
Roche and Hansoh Pharma have signed a major oncology licensing agreement involving antibody-drug conjugates, with more than $15 billion in potential milestone payments.
nuaxia
Oct 202 min read
bottom of page